D.E. Shaw & Co
AXSM icon

D.E. Shaw & Co’s Axsome Therapeutics AXSM Stock Holding History

D.E. Shaw & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Buy
8,600
+4,900
+132% +$1.06M ﹤0.01% 3154
2026
Q1 		$625K Sell
3,700
-5,000
-57% -$864K ﹤0.01% 3729
2025
Q4 		$1.59M Buy
8,700
+2,100
+32% +$293K ﹤0.01% 3223
2025
Q3 		$802K Hold
6,600
– – ﹤0.01% 3597
2025
Q2 		$689K Hold
6,600
– – ﹤0.01% 3478
2025
Q1 		$770K Sell
6,600
-17,700
-73% -$2.02M ﹤0.01% 3254
2024
Q4 		$2.06M Buy
24,300
+9,000
+59% +$828K ﹤0.01% 2711
2024
Q3 		$1.38M Buy
15,300
+5,100
+50% +$445K ﹤0.01% 3018
2024
Q2 		$821K Hold
10,200
– – ﹤0.01% 3311
2024
Q1 		$814K Sell
10,200
-24,400
-71% -$2.05M ﹤0.01% 3228
2023
Q4 		$2.75M Hold
34,600
– – ﹤0.01% 2418
2023
Q3 		$2.42M Hold
34,600
– – ﹤0.01% 2425
2023
Q2 		$2.49M Buy
34,600
+4,000
+13% +$295K ﹤0.01% 2455
2023
Q1 		$1.89M Buy
30,600
+20,600
+206% +$1.35M ﹤0.01% 2733
2022
Q4 		$771K Buy
+10,000
New +$598K ﹤0.01% 3619
2022
Q1 		– Sell
-90,000
Closed -$3.4M – 5519
2021
Q4 		$3.4M Buy
90,000
+60,000
+200% +$2.21M ﹤0.01% 2811
2021
Q3 		$989K Hold
30,000
– – ﹤0.01% 3604
2021
Q2 		$2.02M Hold
30,000
– – ﹤0.01% 2930
2021
Q1 		$1.7M Hold
30,000
– – ﹤0.01% 2730
2020
Q4 		$2.44M Hold
30,000
– – ﹤0.01% 2428
2020
Q3 		$2.14M Hold
30,000
– – ﹤0.01% 2352
2020
Q2 		$2.47M Sell
30,000
-10,000
-25% -$770K ﹤0.01% 2240
2020
Q1 		$2.35M Buy
40,000
+30,000
+300% +$2.44M ﹤0.01% 2029
2019
Q4 		$1.03M Buy
+10,000
New +$404K ﹤0.01% 2962

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co's AXSM Position: Q2 2026 in Review

D.E. Shaw & Co increased its Axsome Therapeutics (AXSM) stake by 0.21% in Q2 2026, buying an estimated $279K and bringing the position to 604,753 shares worth $148M. The position accounts for 0.07% of the portfolio, ranked #296.

D.E. Shaw & Co first reported a position in AXSM in Q2 2019 and has held it in 23 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • D.E. Shaw & Co held 604,753 shares of Axsome Therapeutics worth $148M as of Q2 2026.
  • D.E. Shaw & Co bought 1,288 Axsome Therapeutics shares in Q2 2026, an estimated $279K.
  • Axsome Therapeutics made up 0.07% of D.E. Shaw & Co's portfolio in Q2 2026, its #296 holding.
  • D.E. Shaw & Co first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.